Geode Capital Management
MENS

Geode Capital Management’s Jyong Biotech MENS Stock Holding History

Geode Capital Management’s Portfolio MENS Stock Details MENS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$138K Sell
64,232
-150
-0.2% -$367 ﹤0.01% 4040
2025
Q4 		$254K Buy
64,382
+10,538
+20% +$372K ﹤0.01% 3831
2025
Q3 		$2.12M Buy
+53,844
New +$1.94M ﹤0.01% 3164

Other funds holding MENS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.32B AUM 51.82% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management's MENS Position: Q1 2026 in Review

Geode Capital Management reduced its Jyong Biotech (MENS) stake by 0.23% in Q1 2026, selling an estimated $367 and leaving 64,232 shares worth $138K. The position accounts for ﹤0.01% of the portfolio, ranked #4040.

Geode Capital Management first reported a position in MENS in Q3 2025 and has held it in 3 quarters since. The position peaked at $2.12M in Q3 2025. 17 funds tracked by Wall St. Rank hold MENS as of Q1 2026.

  • Geode Capital Management held 64,232 shares of Jyong Biotech worth $138K as of Q1 2026.
  • Geode Capital Management sold 150 Jyong Biotech shares in Q1 2026, an estimated $367.
  • Jyong Biotech made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #4040 holding.
  • Geode Capital Management first reported a position in Jyong Biotech in Q3 2025 and has held it in 3 quarters since.
  • Geode Capital Management's Jyong Biotech position peaked at $2.12M in Q3 2025.
  • 17 funds tracked by Wall St. Rank held Jyong Biotech as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.